종양 양전자 방출 단층촬영(PET) 시장 : 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰, 예측(2026-2034년)

Growth Factors of oncology positron emission tomography (PET) scan Market

The global oncology positron emission tomography (PET) scan market was valued at USD 12.31 billion in 2025. The market is projected to grow from USD 13.03 billion in 2026 to USD 20.66 billion by 2034, exhibiting a CAGR of 5.93% during the forecast period (2026-2034).

North America dominated the global oncology PET scan market with a 52.40% market share in 2025, supported by advanced diagnostic infrastructure, high cancer prevalence, and strong adoption of innovative imaging technologies.

Oncology PET is a non-invasive molecular imaging technique widely used for cancer detection, staging, therapy assessment, and recurrence monitoring. Rising global cancer burden, increasing demand for diagnostic accuracy, technological advancements, and government-led cancer screening programs are key factors driving market growth.

Market Dynamics

Market Drivers

The rising global burden of cancer is a primary driver of market growth. Increasing incidence of cancers such as prostate, lung, breast, and colorectal cancer has led to a surge in screening programs and demand for advanced diagnostic tools. Governments and healthcare systems are investing heavily in early detection initiatives to reduce mortality and treatment costs.

For instance, updated imaging guidelines and approvals of novel PET imaging agents for prostate cancer have strengthened PET adoption. Additionally, the growing emphasis on personalized medicine and early diagnosis is accelerating the use of oncology PET scans across healthcare settings.

Market Restraints

The high cost of PET scanners and procedures remains a significant restraint. PET scanners can cost between USD 475,000 and over USD 750,000, excluding expenses related to installation, maintenance, radiotracers, and skilled personnel.

Inconsistent reimbursement policies further limit accessibility, particularly in developing economies. Even in developed markets, limited insurance coverage for repeat scans and certain oncology indications restricts utilization, negatively impacting market expansion.

Market Opportunities

The integration of artificial intelligence (AI) and advanced image quantification tools presents a major growth opportunity. AI-enabled PET systems improve lesion detection, tumor characterization, workflow efficiency, and treatment response evaluation.

Continuous innovation, regulatory approvals of AI-based software, and growing adoption of next-generation PET/CT systems are expected to support market development through 2034.

Market Challenges

Radiotracer availability and supply chain constraints pose critical challenges. Radiotracers such as FDG have short half-lives, requiring efficient logistics and proximity to cyclotron facilities. Delays or disruptions can lead to longer patient wait times and reduced scan volumes, limiting market growth.

Market Trends

Shift Toward Theranostics and Personalized Oncology Imaging

A key trend shaping the market is the growing adoption of theranostics, which combines diagnostics and targeted therapy. PET-based theranostic agents, especially PSMA-based tracers for prostate cancer, enable precise diagnosis and real-time therapy monitoring.

Increasing investments in personalized oncology imaging and the development of novel PET tracers are transforming cancer management and driving long-term market growth.

Impact of COVID-19

The COVID-19 pandemic significantly disrupted oncology PET services due to lockdowns and supply chain interruptions. Cancer screening and diagnostic procedures declined sharply, leading to delayed diagnoses.

According to global surveys, PET scan volumes dropped by over 65% in mid-2020, highlighting the pandemic's negative short-term impact. However, post-pandemic recovery and renewed focus on cancer diagnostics have restored market momentum.

Segmentation Analysis

By Source of Payment

The market is segmented into public and private health insurance/out-of-pocket. The private segment dominated the market due to faster access, premium-quality care, and reduced waiting times, especially in countries such as the U.S., Japan, India, and Brazil.

Public healthcare systems are also expanding PET access through increased funding and national cancer control programs.

By Service Provider

Based on service providers, the market includes hospitals, diagnostic centers, and others.

• Hospitals accounted for the largest share in 2025 due to advanced imaging infrastructure and skilled personnel.
• Diagnostic centers are expected to register the fastest growth owing to cost efficiency, specialization, and shorter waiting periods.

Regional Outlook

• North America led the market with USD 6.5 billion in 2025 and USD 6.82 billion in 2026, driven by high cancer prevalence and rapid technology adoption.
• Europe held a substantial share due to strong healthcare systems and increasing approvals of novel PET tracers.
• Asia Pacific is projected to record the highest CAGR through 2034, supported by healthcare infrastructure expansion and government initiatives.
• Latin America and Middle East & Africa are expected to witness steady growth due to rising cancer incidence and improving healthcare investments.

Competitive Landscape

Key players operating in the global oncology PET scan market include GE Healthcare, Siemens Healthcare Limited, Oncovision, Koninklijke Philips N.V., Canon Medical Systems, and Sonic Healthcare Limited. These companies focus on product innovation, strategic collaborations, and regulatory approvals to strengthen their market presence.

Conclusion

The global oncology positron emission tomography scan market is set to grow steadily from USD 12.31 billion in 2025 to USD 20.66 billion by 2034, driven by the rising cancer burden, technological advancements, and increasing focus on personalized oncology imaging. While high equipment costs and radiotracer supply challenges remain key concerns, innovations in AI-enabled imaging, theranostics, and expanding screening programs are expected to sustain long-term market growth. North America will continue to dominate the market, while Asia Pacific is anticipated to emerge as the fastest-growing region during the forecast period.

Segmentation By Source of Payment

• Public
• Private Health Insurance/Out-of-pocket

By Service Providers

• Hospitals
• Diagnostic Centers
• Others

By Region

• North America (By Source of Payment, Service Providers, and Country)
  • U.S.
  • Canada
• Europe (By Source of Payment, Service Providers, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Source of Payment, Service Providers, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Source of Payment, Service Providers, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Source of Payment, Service Providers, and Country/Sub-region)
  • GCC
  • South Africa
• Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Cancer, Key Countries
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
• 4.4. Technological Advancements in Oncology PET

5. Global Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 5.1.1. Public
  • 5.1.2. Private Health Insurance/Out-of-pocket
• 5.2. Market Analysis, Insights and Forecast - By Service Providers
  • 5.2.1. Hospitals
  • 5.2.2. Diagnostic Centers
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 6.1.1. Public
  • 6.1.2. Private Health Insurance/Out-of-pocket
• 6.2. Market Analysis, Insights and Forecast - By Service Providers
  • 6.2.1. Hospitals
  • 6.2.2. Diagnostic Centers
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 7.1.1. Public
  • 7.1.2. Private Health Insurance/Out-of-pocket
• 7.2. Market Analysis, Insights and Forecast - By Service Providers
  • 7.2.1. Hospitals
  • 7.2.2. Diagnostic Centers
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Spain
  • 7.3.5. Italy
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of Europe

8. Asia Pacific Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 8.1.1. Public
  • 8.1.2. Private Health Insurance/Out-of-pocket
• 8.2. Market Analysis, Insights and Forecast - By Service Providers
  • 8.2.1. Hospitals
  • 8.2.2. Diagnostic Centers
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Latin America Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 9.1.1. Public
  • 9.1.2. Private Health Insurance/Out-of-pocket
• 9.2. Market Analysis, Insights and Forecast - By Service Providers
  • 9.2.1. Hospitals
  • 9.2.2. Diagnostic Centers
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 10.1.1. Public
  • 10.1.2. Private Health Insurance/Out-of-pocket
• 10.2. Market Analysis, Insights and Forecast - By Service Providers
  • 10.2.1. Hospitals
  • 10.2.2. Diagnostic Centers
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.3.1. GCC
  • 10.3.2. South Africa
  • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  • 11.2.1. GE Healthcare
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Sonic Healthcare Limited
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Oncovision
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Koninklijke Philips N.V.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Apex Radiology
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Alliance Medical Limited
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Novant Health
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Canon Medical Systems
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Dignity Health
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Concord Medical
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. Siemens Healthcare Limited
    • 11.2.11.1. Overview
    • 11.2.11.2. Products
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)
  • 11.2.12. Mediworks
    • 11.2.12.1. Overview
    • 11.2.12.2. Products
    • 11.2.12.3. SWOT Analysis
    • 11.2.12.4. Recent Developments
    • 11.2.12.5. Strategies
    • 11.2.12.6. Financials (Based on Availability)
  • 11.2.13. Other Prominent Players
    • 11.2.13.1. Overview
    • 11.2.13.2. Products
    • 11.2.13.3. SWOT Analysis
    • 11.2.13.4. Recent Developments
    • 11.2.13.5. Strategies
    • 11.2.13.6. Financials (Based on Availability)